Short-term hemodynamic effects of apelin in patients with pulmonary arterial hypertension
File(s)
Supporting information
Published version
Author(s)
Type
Journal Article
Abstract
Apelin agonism causes systemic vasodilatation and increased cardiac contractility in humans, and improves pulmonary arterial hypertension (PAH) in animal models. Here, the authors examined the short-term pulmonary hemodynamic effects of systemic apelin infusion in patients with PAH. In a double-blind randomized crossover study, 19 patients with PAH received intravenous (Pyr 1 )apelin-13 and matched saline placebo during invasive right heart catheterization. (Pyr 1 )apelin-13 infusion caused a reduction in pulmonary vascular resistance and increased cardiac output. This effect was accentuated in the subgroup of patients receiving concomitant phosphodiesterase type 5 inhibition. Apelin agonism is a novel potential therapeutic target for PAH. (Effects of Apelin on the Lung Circulation in Pulmonary Hypertension; NCT01457170)
Date Issued
2018-04-01
Date Acceptance
2018-01-13
Citation
JACC: Basic to Translational Science, 2018, 3 (2), pp.176-186
ISSN
2452-302X
Publisher
Elsevier
Start Page
176
End Page
186
Journal / Book Title
JACC: Basic to Translational Science
Volume
3
Issue
2
Copyright Statement
© 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an Open Access article under the CC-BY-NC-ND License (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Subjects
APJ
CO, cardiac output
FA, formic acid
NO, nitric oxide
PAEC, pulmonary artery endothelial cells
PAH, pulmonary arterial hypertension
PDE5, phosphodiesterase-5
PVR, pulmonary vascular resistance
SVR, systemic vascular resistance
apelin
human
pulmonary arterial hypertension
Publication Status
Published
Date Publish Online
2018-03-28